These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31913974)

  • 21. Opioid Overdose and Naloxone Kit Distribution: A Quality Assurance Educational Program in the Primary Care Setting.
    Lockett TL; Hickman KL; Fils-Guerrier BJ; Lomonaco M; Maye JP; Rossiter AG
    J Addict Nurs; 2018; 29(3):157-162. PubMed ID: 30180000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an algorithm to identify inpatient opioid-related overdoses and oversedation using electronic data.
    Green CA; Hazlehurst B; Brandes J; Sapp DS; Janoff SL; Coplan PM; DeVeaugh-Geiss A
    Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1138-1142. PubMed ID: 31095831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Legal requirements and recommendations to prescribe naloxone.
    Haffajee RL; Cherney S; Smart R
    Drug Alcohol Depend; 2020 Apr; 209():107896. PubMed ID: 32058248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of acute opioid toxicity in the outpatient setting.
    Reynolds HH; Orlowski TJ; Huang CC; Phillips CB
    Cutis; 2020 Aug; 106(2):68-69. PubMed ID: 32941559
    [No Abstract]   [Full Text] [Related]  

  • 26. An increase in per-patient naloxone requirements in an opioid epidemic.
    Birmingham LE; Nielson JA
    Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907
    [No Abstract]   [Full Text] [Related]  

  • 27. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.
    Fairbairn N; Coffin PO; Walley AY
    Int J Drug Policy; 2017 Aug; 46():172-179. PubMed ID: 28687187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.
    Carpenter J; Murray BP; Atti S; Moran TP; Yancey A; Morgan B
    J Med Toxicol; 2020 Jan; 16(1):41-48. PubMed ID: 31471760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-Based Guidelines for EMS Administration of Naloxone.
    Williams K; Lang ES; Panchal AR; Gasper JJ; Taillac P; Gouda J; Lyng JW; Goodloe JM; Hedges M
    Prehosp Emerg Care; 2019; 23(6):749-763. PubMed ID: 30924736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.
    Torralva R; Janowsky A
    J Pharmacol Exp Ther; 2019 Nov; 371(2):453-475. PubMed ID: 31492824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic Evaluation in Opioid Modeling: Systematic Review.
    Beaulieu E; DiGennaro C; Stringfellow E; Connolly A; Hamilton A; Hyder A; Cerdá M; Keyes KM; Jalali MS
    Value Health; 2021 Feb; 24(2):158-173. PubMed ID: 33518022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Training Program for Law Enforcement K9 Handlers to Administer Naloxone.
    Mitek A; McMichael M; Weir B; Smith M; Schneider D; Schaefer D
    J Am Anim Hosp Assoc; 2020; 56(4):197-205. PubMed ID: 32412334
    [No Abstract]   [Full Text] [Related]  

  • 33. Basic and Advanced EMS Providers Are Equally Effective in Naloxone Administration for Opioid Overdose in Northern New England.
    Gulec N; Lahey J; Suozzi JC; Sholl M; MacLean CD; Wolfson DL
    Prehosp Emerg Care; 2018; 22(2):163-169. PubMed ID: 29023172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naloxone nasal spray.
    Drug Ther Bull; 2019 Sep; 57(9):137-140. PubMed ID: 31296655
    [No Abstract]   [Full Text] [Related]  

  • 35. Preventing opioid overdose with peer-administered naloxone: findings from a rural state.
    Hanson BL; Porter RR; Zöld AL; Terhorst-Miller H
    Harm Reduct J; 2020 Jan; 17(1):4. PubMed ID: 31918740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementing an Opioid Risk Reduction Program in the Acute Comprehensive Inpatient Rehabilitation Setting.
    Van SP; Yao AL; Tang T; Kott M; Noles A; Dabai N; Coslick A; Rojhani S; Sprankle LA; Hoyer EH
    Arch Phys Med Rehabil; 2019 Aug; 100(8):1391-1399. PubMed ID: 31121153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of overdose in the synthetic opioid era.
    Skolnick P
    Pharmacol Ther; 2022 May; 233():108019. PubMed ID: 34637841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nationwide pharmacy chain responds to the opioid epidemic.
    Shafer E; Bergeron N; Smith-Ray R; Robson C; O'Koren R
    J Am Pharm Assoc (2003); 2017; 57(2S):S123-S129. PubMed ID: 28163028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid overdose prevention training with naloxone, an adjunct to basic life support training for first-year medical students.
    Berland N; Fox A; Tofighi B; Hanley K
    Subst Abus; 2017; 38(2):123-128. PubMed ID: 28027016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementing an overdose education and naloxone distribution program in a health system.
    Devries J; Rafie S; Polston G
    J Am Pharm Assoc (2003); 2017; 57(2S):S154-S160. PubMed ID: 28233681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.